Macbee Planet (7095) Q3 2025 earnings summary
Event summary combining transcript, slides, and related documents.
Q3 2025 earnings summary
24 Jul, 2025Executive summary
Net sales for Q3 FY2025 rose 32% year-over-year to ¥38,381mn, with operating profit up 14% to ¥3,629mn and profit attributable to owners of parent up 0.5% to ¥2,105mn.
Growth was driven by both existing and new clients, with the LTV Marketing segment achieving net sales of ¥37,710mn (up 30.5%) and segment profit of ¥5,191mn (up 19.1%).
Medical sector sales surpassed expectations, while Finance and Talent sectors saw large campaigns and steady expansion.
Moved to Tokyo Stock Exchange Prime Market, executed a 4-for-1 stock split, and repurchased 617,800 treasury shares.
Initiated share buybacks and introduced regular dividends.
Financial highlights
Q3 FY2025 net sales: ¥38,381mn, up 32% YoY; EBITDA: ¥4,088mn, up 16%; operating profit: ¥3,629mn, up 14%.
Gross profit increased to ¥6,954mn from ¥5,732mn YoY; gross profit margin for Q3 FY2025 was 17.9%, down from 19.6% in Q3 FY2024.
Ordinary profit rose 13.4% to ¥3,592mn; comprehensive income grew 12.7% YoY to ¥2,255mn.
EPS for Q3 FY2025 was ¥147.93, compared to ¥146.11 in the prior year period.
Profit per share forecast for FY2025 revised to ¥187.57–¥211.70, up from ¥158.77 in FY2024.
Outlook and guidance
FY2025 net sales forecast revised upward to ¥53,000mn (+35% YoY); operating profit forecast to ¥4,700mn (+28% YoY); profit attributable to owners of parent at ¥2,770mn (+21.3% YoY).
Profit per share for the full year is forecast at ¥195.80.
Growth rate for FY2025 expected to exceed mid-term business plan targets.
Further expansion anticipated in Finance and Talent sectors in Q4.
Preparing for voluntary adoption of IFRS in FY2026, with full-year FY2025 results under J-GAAP.
Latest events from Macbee Planet
- Revenue and profit fell sharply year-over-year, but full-year guidance is maintained.7095
Q3 202613 Mar 2026 - Operating profit and margin fell as revenue growth slowed, leading to a downward forecast revision.7095
Q2 202611 Dec 2025 - Q1 revenue up 11% year-over-year, but profit fell sharply on higher ad costs; recovery forecast.7095
Q1 202611 Sep 2025 - Sales and profits more than doubled, with strong outlook and a 4-for-1 stock split ahead.7095
Q4 202424 Jul 2025 - Record sales and profit growth, led by medical and LTV Marketing, with a major share buyback.7095
Q1 202524 Jul 2025 - Sales up 30% in 1H, with strong growth in medical, finance, and LTV Marketing.7095
Q2 202524 Jul 2025 - Record sales and profit growth, with strong FY2026 outlook and expanded shareholder returns.7095
Q4 202524 Jul 2025